Healthequity (HQY) Research & Development (2013 - 2026)

Healthequity's Research & Development history runs 14 years deep, the most recent figure standing at $67.8 million for Q2 2026.

• In Q2 2026, Research & Development rose 10.31% year-over-year to $67.8 million; the TTM figure through Apr 2026 stood at $268.8 million (up 9.79% YoY), while the FY2026 annual figure was $262.5 million, up 9.6% from the prior year.
• Research & Development was $67.8 million for Q2 2026 at Healthequity, down from $70.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $70.4 million in Q1 2026 to a low of $45.2 million in Q2 2022.
• Historically, Research & Development has averaged $57.1 million across 5 years, with a median of $55.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 42.11% in 2022, then climbed 4.77% in 2024.
• A 5-year view of Research & Development shows it stood at $48.9 million in 2022, then advanced by 13.75% to $55.6 million in 2023, then grew by 8.23% to $60.2 million in 2024, then advanced by 9.52% to $65.9 million in 2025, then grew by 2.81% to $67.8 million in 2026.
• The last three Research & Development figures came in at $67.8 million (Q2 2026), $70.4 million (Q1 2026), and $65.9 million (Q4 2025), per Business Quant data.